$IFRX looks great but didn't someone post the official June PR saying endpoint of the trial missed and the trial was a fail. Wouldn't this new data mean a brand new expensive trial needed to go forward? Wouldn't that burn through the nice cash position? Think the new good data simply means regulators will support them moving forward with a new trial and nothing more. Thoughts? This feels like a dump coming in the am to me.
  • 5